Templated misfolding of Tau by prion-like seeding along neuronal connections impairs neuronal network function and associated behavioral outcomes in Tau transgenic mice by Stancu, Ilie-Cosmin et al.
1 3
Acta Neuropathol
DOI 10.1007/s00401-015-1413-4
ORIGINAL PAPER
Templated misfolding of Tau by prion‑like seeding along neuronal 
connections impairs neuronal network function and associated 
behavioral outcomes in Tau transgenic mice
Ilie‑Cosmin Stancu1 · Bruno Vasconcelos1 · Laurence Ris2 · Peng Wang1 · 
Agnès Villers2 · Eve Peeraer3 · Arjan Buist3 · Dick Terwel4 · Peter Baatsen5 · 
Tutu Oyelami3 · Nathalie Pierrot1 · Cindy Casteels6 · Guy Bormans6 · 
Pascal Kienlen‑Campard1 · Jean‑Nöel Octave1 · Diederik Moechars3 · Ilse Dewachter1 
Received: 29 September 2014 / Revised: 11 March 2015 / Accepted: 12 March 2015 
© The Author(s) 2015. This article is published with open access at Springerlink.com
mice demonstrated impaired synaptic transmission and 
impaired long-term potentiation following Tau-seed 
induced Tau-aggregation. Intracerebral injection of Tau-
seeds in TauP301S mice, caused prion-like spreading of 
Tau-pathology through functionally connected neuroana-
tomical pathways. Electrophysiological analysis revealed 
impaired synaptic plasticity in hippocampal CA1 region 
6 months after Tau-seeding in entorhinal cortex (EC). Fur-
thermore, templated Tau aggregation impaired cognitive 
function, measured in the object recognition test 6 months 
post-seeding. In contrast, Tau-seeding in basal ganglia 
and subsequent spreading through functionally connected 
neuronal networks involved in motor control, resulted in 
motoric deficits reflected in clasping and impaired inverted 
grid hanging, not significantly affected following Tau-
seeding in EC. Immunostaining, biochemical and electron 
microscopic analysis in the different models suggested 
early pathological forms of Tau, including Tau-oligomers, 
rather than fully mature neurofibrillary tangles (NFTs) as 
culprits of neuronal dysfunction. We here demonstrate for 
the first time using in vitro, ex vivo and in vivo models, 
that prion-like spreading of Tau-misfolding by Tau seeds, 
along unique neuronal connections, causes neuronal net-
work dysfunction and associated behavioral dysfunction. 
Our data highlight the potential relevance of this mecha-
nism in the symptomatic progression in Tauopathies. We 
furthermore demonstrate that the initial site of Tau-seed-
ing thereby determines the behavioral outcome, poten-
tially underlying the observed heterogeneity in (familial) 
Tauopathies, including in TauP301 mutants.
Keywords AD · Tauopathies · Tau · Prion-like 
propagation · Tau-pathology · Neuronal network · 
Synaptic · Cognition · Motoric deficits · TauP301 
heterogeneity
Abstract Prion-like seeding and propagation of Tau-
pathology have been demonstrated experimentally and 
may underlie the stereotyped progression of neurodegen-
erative Tauopathies. However, the involvement of tem-
plated misfolding of Tau in neuronal network dysfunc-
tion and behavioral outcomes remains to be explored in 
detail. Here we analyzed the repercussions of prion-like 
spreading of Tau-pathology via neuronal connections on 
neuronal network function in TauP301S transgenic mice. 
Spontaneous and GABAAR-antagonist-induced neu-
ronal network activity were affected following templated 
Tau-misfolding using synthetic preformed Tau fibrils in 
cultured primary neurons. Electrophysiological analy-
sis in organotypic hippocampal slices of Tau transgenic 
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Introduction
Tauopathies are a diverse group of neurodegenerative dis-
eases, characterized by the presence of Tau aggregates 
composed of misfolded hyperphosphorylated Tau [7, 41, 
62]. In Tauopathies, symptoms correlate strongly with the 
regional distribution of Tau-aggregates in the brain. In Alz-
heimer’s Disease, the most common Tauopathy, Tau aggre-
gate formation progresses in a stereotypic pattern, along 
functionally connected neuroanatomical pathways, used 
for staging disease progression [2, 6, 34, 59]. In AD, Tau 
pathology starts in the entorhinal cortex (EC), progresses 
to the limbic regions such as subiculum, hippocampal 
cornu ammonis (CA) and amygdala (stages III and IV), 
and finally involves neocortical areas (stages V and IV), 
according to the Braak and Braak stages [6, 59]. Defects 
in neuronal function and neuronal loss of the affected or 
connected neurons are believed to contribute to the disease 
symptoms by affecting functionally critical neuronal net-
works, while the mechanism remains poorly understood [6, 
15, 24, 58, 74].
Accumulating evidence indicates that Tau and related 
proteins linked to neurodegenerative proteinopathies dis-
play prion-like properties [12–14, 19, 22, 25, 26, 28, 32, 
35, 37, 72]. In vitro studies have demonstrated that extra-
cellular misfolded Tau can be taken up by cultured cells, 
can seed aggregation of endogenous soluble Tau and can 
propagate a fibrillar, misfolded state between co-cultured 
cells [20, 26, 32, 53]. Injections of brain lysates from neu-
rofibrillary tangle (NFT) bearing transgenic mice into wild 
type Tau-expressing transgenic mice that do not develop 
NFTs, induce Tau pathology that spreads to brain regions 
remote from the injection site by connectivity rather than 
proximity [1, 13]. This has been recapitulated with brain 
extracts from patients with different Tauopathies, mim-
icking distinct forms of Tau-aggregation—in a cell-type 
and region specific way-reminiscent for the respective 
Tauopathies [5, 12]. Injection of pre-aggregated synthetic 
full length Tau and Tau fragments results in seeding and 
spreading of Tau-pathology in cells and in Tau transgenic 
mice, demonstrating that misfolded Tau per se, and not a 
different factor in the brain extracts, is sufficient to induce 
Tau-aggregation [35]. Induction of Tau-aggregation by 
misfolded Tau has been demonstrated in non-transgenic 
mice [40], albeit at later age and to a more limited extent. 
Indefinite and stable maintenance of unique conforma-
tions—“strains”—in vivo that link structure to patterns of 
pathology was recently demonstrated, further corroborat-
ing prion-like properties of misfolded Tau [5, 53]. Although 
increasing dysfunction in neuronal networks is believed to 
explain the progression of behavioral disease symptoms, 
including memory loss [22, 28, 53, 58, 59], it remains to 
be demonstrated whether this can be caused by prion-like 
spreading of Tau-pathology. This is not a trivial question, 
as previous reports have indicated that NFTs per se may not 
disturb neuronal function and could be an off-pathway dis-
ease side effect [30, 38, 48, 52, 54, 61, 65, 66, 69].
In this work, we have addressed this question using 
in vitro, ex vivo and in vivo models with induction and 
spreading of Tau-pathology. Seeding of Tau pathology 
was shown to impair neuronal network function in primary 
neuronal cultures and in organotypic hippocampal slices. 
Furthermore, Tau-seeding caused prion-like spreading of 
Tau-aggregation through functionally connected neuronal 
networks and neuronal network dysfunction in TauP301S 
transgenic mice, leading to either cognitive or motoric 
deficits, depending on the initial site of Tau-seeding. Our 
data furthermore point to early pathological forms of Tau, 
including Tau oligomers, rather than somatic NFTs as cul-
prits for the functional deficits.
Materials and methods
Animals
Transgenic TauP301S mice (PS19) [73] expressing human 
Tau-P301S (1N4R), driven by the mouse prion protein pro-
moter were backcrossed to C57B6 and used in this study. 
TauP301S mice bred and used in our lab, develop a neu-
rodegenerative phenotype similar as previously reported, at 
~10–11 months [35, 63, 73]. Stereotactic injections were 
performed at 3 months and age-matched littermates were 
used for analysis at different time points post-injection. All 
experiments were performed in compliance with protocols 
approved by the UCLouvain Ethical Committee for Animal 
Welfare.
Tau aggregation assays
Generation of Tau-PFFs from recombinant Tau Tau-PFFs 
(synthetic preformed fibrils) or Tau-seeds were generated 
as described [26, 35]. Briefly, truncated human Tau frag-
ments (WT-Tau/P301L-Tau) containing the four repeat 
domain [K18; Q244-E372 (4RTau)], N-terminally Myc-
tagged were produced in Escherichia coli. Tau-PFFs were 
obtained by incubation of Tau fragments (66 μM) at 37 °C 
for 5 days in the presence of heparin (133 μM) in 100 mM 
ammonium acetate buffer (pH 7.0). Following centrifuga-
tion (100,000g, 1 h, 4 °C), the pellet was resuspended in 
the same buffer (333 µM final) and sonicated before use. 
Tau fibrilization was confirmed using ThioT assay (Sigma-
Aldrich, St. Louis, MO, USA) and immunoblotting. In 
vitro Tau aggregation assay in HEK293 cells PFFs induced 
Tau-aggregation in vitro was essentially performed as pre-
viously [26]. Sonicated Tau-seeds (10 μM) were added to 
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Bio-PORTER single use tubes (AMS Biotechnology, Mil-
ton, UK) and added to optiMEM-washed transiently trans-
fected HEK293 (QBI) cells, 24 h post-transfection with Tau 
(P301L or WT). In vitro Tau-aggregation assay in primary 
neurons Primary cortical neuronal cultures (PNC) were 
generated as described previously [55], from P0 heterozy-
gous TauP301S pups or non-transgenic (WT) littermates. 
Tau-seeds (10 nM) were added at DIV3 and DIV6, and pri-
mary neurons were used for calcium imaging at DIV13 and 
subsequently extracted or fixed for further analysis. Ex-vivo 
Tau-aggregation assay in organotypic hippocampal slices 
Organotypic hippocampal slices (OC) were generated 
using previously described protocols [21, 64]. Briefly, hip-
pocampal slices were generated at P6 from heterozygous 
TauP301S mice and non-transgenic littermates. Tau-seeds 
(1 µL; 333 µM) were gently added on top of hippocampal 
slices at DIV3 and DIV6, and slices were analyzed elec-
trophysiologically, biochemically and immunohistologi-
cally 10 days after seeding. Tau-seeded Tau-aggregation in 
vivo Sonicated pre-aggregated Tau-PFFs (5 µL; 333 µM) 
or vehicle without seeds (5 µL) were injected in 3 months 
old mice. Stereotactic injections were performed in the hip-
pocampal CA1 region (A/P, −2.0; L, +1.4; D/V, −1.2), 
frontal cortex (A/P, +2.0; L, +1.4; D/V, −1.0), in entorhi-
nal cortex (A/P, −4.8; L, −3.0; D/V, −3.7) and substantia 
nigra (A/P, −4.8; P/A, angle 16°; L, −1.1; D/V, −4.7) mil-
limeter relative to bregma [45], using a 10 µL Hamilton 
syringe at a speed of 1 μL per min.
Biochemical analysis
For immunoblotting analysis brain regions were dissected 
and snap-frozen in liquid nitrogen, and subsequently differ-
ential extraction of total homogenates, sarkosyl soluble and 
sarkosyl insoluble fractions was performed as previously 
described [67, 68] and in supplemental data. Similar extrac-
tion procedures were used for primary neurons and organo-
typic cultures as described in supplemental data. Proteins 
were quantified using BCA Protein Assay kit (Thermo 
Fisher Scientific, Waltham, MA, USA). For dot blotting 
equal amounts of total homogenates were spotted on a 
nitrocellulose membrane and subsequently immunoblotted 
using T22 [ABN454 Anti-Tau (T22) oligomeric antibody; 
EMD Millipore], against oligomeric Tau [39]. Analysis 
under non-denaturating and non-reducing conditions was 
performed on 4-16 % Bis-Tris Native Page. For immunob-
lotting equal amounts of proteins were loaded on precasted 
gels [4–12 % (MOPS), 8 % Tris–glycine gel (Invitrogen, 
Life Technologies, Carlsbad, CA, USA)]. Immunoblotting 
was performed with anti-Tau P-S202/T205 (AT8; Thermo 
Fisher Scientific, Waltham, MA, USA), with anti-Tau 
P-S396/S404 antibody (AD2; Bio-Rad Laboratories Inc., 
Hercules, CA, USA), or with anti-total Tau antibody (HT7; 
Thermo Fisher Scientific, Waltham, MA, USA) and devel-
oped using ECL kit (PerkinElmer, Waltham, MA, USA).
Immunohistological and immunocytological analysis
Immunohistological analysis was performed as described 
previously [16, 17, 36, 49, 63]. Following transcar-
dial flushing (2 min), brains were dissected and immer-
sion fixed in 4 % paraformaldehyde in PBS for 24 h at 
4 °C. Sagittal sections (40 µm) were cut on a vibrating 
HM650V microtome (Thermo Fisher Scientific, Waltham, 
MA, USA). Immunohistochemistry (IHC) with anti-Tau 
P-S202/T205 (AT8), anti-Tau P-S212/T214 (AT100) and 
anti-conformational specific Tau (MC1, Peter Davies) was 
done on 40 µm sagittal vibratome sections using appropri-
ate Alexa coupled secondary antibodies (Invitrogen, Life 
Technologies, Carlsbad, CA, USA). Staining with Thi-
oflavin S (ThioS; Sigma-Aldrich, St. Louis, MO, USA) 
and Gallyas silver staining were performed as previously 
described [63]. Image acquisition was performed using a 
digital inverted fluorescence microscope EVOS-xl micro-
scope (Life Technologies, Carlsbad, CA, USA), using a 
4×, 10×, 20× or 40× lens, and standard light microscope. 
Image analysis was done using Image J (National Institutes 
of Health). Heat maps were generated using the HeatMap 
Histogram plugin for Image J. Briefly, the overview images 
of AT8 staining of a well-identified section of different 
mice (n ≥ 3 per group) were grouped. Stacked images 
representing averaged intensities were generated using the 
Image J stacking tool with the average intensities outcome 
option. Finally, a Gaussian Blur filter of 5.0 was applied. 
Immunocytochemistry (ICC) and IHC on HEK293 cells, 
primary neurons and organotypic cultures were performed 
similarly. Fixation was performed standard or under strin-
gent extraction of soluble Tau (supplemental material). All 
other chemicals were from Sigma-Aldrich (Sigma-Aldrich, 
St. Louis, MO, USA).
Neuronal network activity‑synchronized cytosolic 
calcium oscillations
Primary neurons from P0, TauP301S mice and non-trans-
genic littermates were used for calcium imaging, using 
incubation with fura-2 acetoxymethylester (Fura-2 AM; 
Calbiochem, Camarillo, CA, USA) 2 μM (final) in Krebs-
HEPES buffer (10 mM HEPES, 135 mM NaCl, 6 mM KCl, 
2 mM CaCl2, 1.2 mM MgCl2, 10 mM glucose, pH 7.4) 
for 30 min at RT. Coverslips were then washed in Krebs–
HEPES buffer and mounted in a heated (37 °C) microscope 
chamber with 600 µL of buffer [44, 55]. After recording of 
basal spontaneous calcium oscillations, picrotoxin (PTX; 
Sigma-Aldrich, St. Louis, MO, USA) was added to the 
neurons to a final concentration of 100 µM for 3 min. Cells 
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were alternately excited (1 or 2 Hz) at 340 and 380 nm for 
100 ms using a Lambda DG-4 Ultra High Speed Wave-
length Switcher (Sutter Instrument, Novato, CA, USA) 
coupled to a Zeiss Axiovert 200 M inverted microscope 
(20x fluorescence objective) (Carl Zeiss AG, Oberkochen, 
DE). Images were acquired with a Zeiss Axiocam camera 
coupled to a 510 nm emission filter and analyzed with the 
AxioVision software. Calcium concentration was evalu-
ated from the ratio of fluorescence emission intensities 
excited at the two wavelengths, i.e. the ratio of F340/F380. 
Changes in the intracellular calcium fluorescence were 
expressed as ΔF/F0 to represent the changes in the cyto-
solic calcium concentrations, relative to the resting fluores-
cence value F0. Calcium oscillations were defined as varia-
tions of more than 10 % from F0, occurring synchronously 
in several cells of the field.
Functional analysis
Electrophysiology Electrophysiological analysis in organo-
typic hippocampal slices was performed on non-seeded 
(vehicle) or Tau-seeded cultured hippocampal slices (at 
DIV3 and DIV6) from WT or TauP301S P6 pups and ana-
lyzed after the indicated time post-seeding (2, 4, 10 days). 
Cultures were directly placed into the recording cham-
ber and slices were kept in interface at 28 °C for 30 min 
before recordings. Electrophysiological analysis in acute 
hippocampal slices derived from seeded and non-seeded 
mice was performed essentially as described previously 
[17, 63]. Briefly, hippocampus was dissected and cut in 
450 µm-thick slices with a tissue chopper. The slices were 
transferred into the recording chamber and kept in interface 
at 28 °C for 90 min. Electrophysiological recordings Hip-
pocampal slices were perfused with artificial cerebrospi-
nal fluid (ACSF) with the following composition: 124 mM 
NaCl, 5 mM KCl, 26 mM NaHCO3, 1.24 mM NaH2PO4, 
2.5 mM CaCl2, 1.3 mM MgSO4, 10 mM glucose, bubbled 
with a mixture of 95 % O2 and 5 % CO2. The perfusion rate 
of ACSF was 1 mL/min. A bipolar twisted nickel-chrome 
electrode (50 µm diameter) was used to stimulate Schaf-
fer’s collaterals. Extracellular field excitatory postsynap-
tic potentials (fEPSP) for acute slices or population spikes 
(PS) for organotypic slices were recorded in the stratum 
radiatum of the CA1 region with low resistance (2–5 MΩ) 
glass microelectrodes filled with ACSF. The slope of the 
fEPSP or the amplitude of PS was measured on the aver-
age of four consecutive responses. LTP was induced by 
applying one train of high-frequency stimulation (100 Hz, 
1 s). Stimulation, data acquisition and analysis were per-
formed using the WinLTP program 28 (website: http://
www.winltp.com). For each slice, the fEPSP slopes or PS 
amplitudes were normalized with respect to the mean slope 
of the fEPSPs or the mean amplitude of the PS recorded 
during the 30 min period preceding induction of LTP. 
Statistical analysis of the data was performed using one-
way ANOVA or Student’s t test in SigmaPlot 12.0 soft-
ware (Systat Software Inc, Chicago, IL, USA). Data were 
expressed as mean ± SEM, and differences with p < 0.05 
Fig. 1  Tau-seed induced Tau aggregation affected neuronal network 
activity in primary neurons. a Tau-seeding in primary neurons from 
TauP301S mice (Tau-seeded) induced somatic accumulation of aggre-
gated Tau, as detected by AT8 staining following stringent extraction 
to eliminate soluble Tau, in ~5–10 % of the neurons. AT8 staining 
was not detected in non-seeded TauP301S neurons (Tau) or neurons 
derived from non-transgenic mice (WT) (scale bar 100 µm). b Cal-
cium oscillations in primary neurons were visualized using Fura-
2AM [expressed as background corrected increase in fluorescence 
divided by the resting fluorescence (ΔF/F0)] for the indicated condi-
tions. Representative traces of spontaneously oscillating neurons for 
each condition (WT neurons, Tau-expressing neurons, Tau-seeded 
Tau-expressing neurons), reveal higher amplitudes, higher synchro-
nicity, and more regularly shaped oscillations in Tau-seeded neurons, 
compared to Tau and to WT neurons. Application of picrotoxin (PTX) 
increased amplitudes of oscillations, the synchronicity and the shape 
of the oscillations. Mean amplitudes were significantly lower in Tau-
seeded neurons following PTX administration compared to Tau and 
WT neurons. Quantitative analysis of amplitudes in the presence and 
absence of PTX are presented for the different conditions [number of 
neurons measured per condition (n = 47 (WT); n = 66 (Tau); n = 68 
(Tau-seeded); experiments (n = 3); mean ± SEM are presented; **p 
value <0.01, ***p value <0.001]
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were considered significant. FDG-PET analysis Brain glu-
cose metabolism was assessed using [18F]FDG (FDG) as 
described in detail in supplemental data [9].
Behavioral testing
The object recognition task The object recognition task 
was essentially performed as previously described [17, 51]. 
Briefly, following 10 min habituation to the open field box 
(60 × 60 × 50 cm), the mice were submitted the next day to 
a 10 min acquisition trial. During this trial, mice were placed 
in the open field in the presence of object A, and the time 
spent exploring object A was measured. During a 10 min 
retention trial performed 1 h later, a novel object B was 
added to the arena. The recognition index (RI), defined as 
the ratio of the time spent exploring the novel object B over 
the time spent exploring both objects [(tB/(tA + tB)) × 100] 
was used to measure nonspatial memory [17]. Clasping scor-
ing Scoring of clasping was performed using a scale between 
5 and 1, with clasping score 5 representing no clasping (nor-
mal), score 4 representing initial signs of clasping, score 3 
for intermediate clasping, score 2 for strong clasping, and 
score 1 representing very severe (maximal) clasping. Scores 
between 1 and 5 were assigned by an experimentator blinded 
for the experimental group. Inverted grid hanging task The 
inverted grid hanging test was used to assess the ability to 
grasp an elevated horizontal grid and to remain suspended 
for 2 min. The grid (40 cm × 20 cm/0.5 cm meshes) was 
positioned 50 cm above a flat, soft surface and the latency for 
the animal to drop off was measured.
Immunogold electron microscopy
Protein extracts from mouse brains, PNC, OC and HEK293 
cells were applied on 300-mesh carbon-coated grids 
in drops of 3 µL for 5 min, blotted on a filter paper and 
air-dried before the immunogold procedure. Grids were 
blocked in PBS, 0.1 % cold water fish gelatin (PBS-
CWFG) for 5 min before incubating with PBS-CWFG 
diluted primary antibodies (HT7 1:50, AT8 1:50, AT100 
1:50) for 90 min at RT. After washing 5 times (2 min) in 
PBS-CWFG, grids were incubated for 60 min with second-
ary antibody (goat anti-mouse IgG) labeled with 10-nm 
gold particles (Aurion) diluted 1:30 in PBS-CWFG. Fol-
lowing washes in PBS and dH2O, grids were negatively 
stained with 2 % uranyl acetate for 1 min. The grids were 
examined with a JEOL JEM1400 transmission electron 
microscopy equipped with a Olympus SIS Quemesa 11 
Mpxl camera, and images were taken at magnifications 
of 20× and 30× k (resp. pixel size = 0.72 and 0.48 nm). 
Immuno-gold electron-microscopy on brain slices is 
described in detail in supplemental data.
Fig. 2  Synthetic Tau seed induced Tau-aggregation impaired basal 
synaptic transmission and synaptic plasticity in organotypic hip-
pocampal slices. a Tau-aggregation induced by Tau-seeding at 
DIV3 and DIV6 in organotypic hippocampal slices derived from 
P6 heterozygous TauP301S transgenic pups. AT8 staining revealed 
robust AT8 staining in hippocampal CA1 region 10 days after seed-
ing of TauP301S organotypic cultures [Tau-seeded (10 days)], not 
detected in neurons of non-seeded TauP301S organotypic cultures 
(Tau), short application (1 h) of Tau-seeds [Tau-seeded (short (1 h)] 
on TauP301S organotypic cultures (OC) or organotypic cultures 
derived from non-transgenic mice (WT) with or without Tau-seeding 
(10 days) (lower panel) (scale bar ×10—400 µm, ×20—200 µm). 
b Population spike (PS) measurement in CA1 following stimulation 
of Schaffer collaterals. Amplitudes of population spikes were sig-
nificantly decreased 10 days after seeding in Tau-seeded compared to 
non-seeded TauP301S cultures [n = 15 (Tau); n = 17 (Tau-seeded); 
mean ± SEM are presented; *p value <0.05]. LTP of the population 
spike amplitude measured following tetanic stimulation of Schaffer 
collaterals was significantly impaired 10 days after seeding in Tau-
seeded compared to non-seeded slices [n = 3 (Tau); n = 5 (Tau-
seeded); mean ± SEM are presented; p value <0.05]. Amplitudes 
of population spikes were not significantly altered at 2 days [Tau 
(n = 6), Tau-seeded (n = 9)] or 4 days [Tau (n = 11), Tau-seeded 
(n = 9)] after Tau-seeding in TauP301S cultures or in non-transgenic 
(wild-type, WT) cultures 10 days after Tau-seeding [WT (n = 10); 
WT + Tau-seeds (n = 7)]
 Acta Neuropathol
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Statistical analysis
Statistical analysis was performed using GraphPad Prism 
5.0 (GraphPad Software, San Diego, CA, USA) using one-
way analysis of variance (ANOVA) followed by Dunnett’s 
post hoc test and Student’s t test. Data were expressed as 
mean ± SEM and differences were considered significant 
when p values <0.05.
Results
Synthetic Tau‑fibrils induce Tau‑aggregation 
and altered neuronal network activity in primary 
neuronal cultures
Tau seeds extracted from brains of Tau transgenic mice 
with Tau pathology, from patients with different forms 
of Tauopathies or pre-aggregated synthetic Tau and Tau-
fragments [12, 13, 35] induce Tau-aggregation in cultured 
cells and in vivo [19, 22, 26, 28, 53]. In this work, we 
used synthetic pre-aggregated Tau fragments, encompass-
ing the four repeat domain of TauP301L, further referred 
to as “Tau-seeds”, to analyze the functional repercussions 
of Tau-aggregation in different in vitro, ex vivo and in 
vivo models. We first acquired and characterized Tau-seed 
induced Tau-aggregation in HEK293 cells, by administra-
tion of Tau-seeds to transfected TauP301L HEK293 cells 
using BioPORTER as previously shown [26]. Biochemical 
analysis demonstrated the presence of detergent insoluble 
(Triton-insoluble (TX-100) and sarkosyl insoluble) Tau-
aggregates phosphorylated at S202/T205 (AT8) (Fig. S1a) 
following Tau-seeding while absent in non-seeded cells. 
Tau aggregation was further confirmed by immunocyto-
chemical (ICC) analysis using a stringent extraction pro-
tocol with TX-100, extracting soluble forms of Tau from 
the cells, while only aggregated forms of Tau remained 
detectable. Staining with anti-Tau P-S202/T205 antibody 
(AT8) demonstrated intense staining of Tau aggregates in 
seeded cells, absent in non-seeded cells (Fig. S1a). Since 
the AT8 epitope is situated outside of the Tau-seeding frag-
ment, this demonstrates aggregation of full length Tau and 
not accumulation of Tau-seeds in the cells. To determine 
optimal conditions for Tau-aggregation, we used differ-
ent combinations of wild type Tau and mutant TauP301L 
forms as inducer and receiver. Immunocytological and 
alpha-LISA analysis demonstrated that wild type Tau was 
markedly less prone to aggregate than TauP301L (recipi-
ent), when seeded with either wild type or P301 mutated 
pre-aggregated Tau-seeds (inducer) (Fig. S1b). Similarly, 
wild-type Tau seeds (inducer) were less efficient com-
pared to mutated TauP301L seeds, in inducing Tau-aggre-
gation (Fig. S1b, c). Hence, in this work, we analyzed the 
functional repercussions of Tau-aggregation in optimal 
conditions, using Tau mutated at Proline 301 acting both as 
inducer and recipient.
To analyze the effect of Tau-seed induced Tau-aggre-
gation on neuronal network function, we performed Tau-
seeding in primary neurons derived from TauP301S trans-
genic mice [27, 63, 73]. Addition of Tau-seeds—without 
BioPORTER—induced Tau-aggregation in primary Tau-
expressing neurons 10 days post-seeding. Tau-aggregation 
was demonstrated using AT8 staining following strin-
gent extraction, demonstrating strong somatic AT8 stain-
ing in Tau-expressing cultures following Tau-seeding. No 
AT8 positive neurons were detected in non-seeded Tau-
expressing neurons or seeded and non-seeded wild type 
neurons (Fig. 1a, Fig. S2). To assess if Tau-seeded Tau-
aggregation affected neuronal network activity, we meas-
ured synchronized calcium oscillations using Fura-2 AM 
Fig. 3  In vivo aggregation of Tau following injection of Tau-seeds. 
a Tau-seeding induced Tau-aggregation in vivo. I Intracerebral injec-
tion of Tau-seeds in frontal cortex and hippocampus (not shown) at 
3 months in TauP301S transgenic mice induced robust Tau-pathology 
6 months post-injection, in contrast to buffer only injected TauP301S 
mice or non-injected TauP301S mice (not shown). Representative 
AT8 stainings are shown (magnification ×4, ×10, ×20). Staining 
with AT100, Gallyas silver and ThioS are presented (magnification 
×20) (scale bar ×4—1000 µm, ×10—400 µm, ×20—200 µm). II 
Biochemical analysis revealing Tau-seed induced Tau-aggregation, 
as demonstrated by immunoblotting of sarkosyl soluble and sarkosyl 
insoluble fractions of brain extracts. Total levels of sarkosyl soluble 
Tau were not significantly affected following Tau seeding, but show 
increased ratio of higher MW to lower MW Tau forms. Marked 
increase in sarkosyl insoluble Tau following Tau-seeding as revealed 
by immunoblotting with HT7 (total Tau) antibody, AT8 (P-S202/
T205) antibody and with AT270 (P-T181) antibody of sarkosyl insol-
uble fractions extracted from brains of Tau-seeded mice, 6 months 
post-injection, compared to non-seeded Tau mice. Sarkosyl insoluble 
Tau displayed a characteristic shift in mobility compared to sarko-
syl insoluble Tau (arrows indicate 68 kDa). b Progressive spread-
ing of Tau-pathology. Longitudinal analysis at different post-injec-
tion (p.i.) times (1.5 mo, 2.5 mo, 3.5 mo and 6 mo post-injection). 
Tau-pathology revealed by AT8 staining spreads progressively from 
entorhinal cortex (EC) to functionally connected hippocampal regions 
(CA1, CA3, DG, Sub) and amygdala (AA). At 1.5 mo p.i. NFTs are 
mainly restricted to EC. Note that weak axonal staining (indicated 
with asterisk) of mossy fibers and in DG (at 1.5 mo p.i.), does not 
represent NFTs but axonal staining observed in young TauP301S 
mice [73]. I Tau-pathology progressively spreads to the contralat-
eral hemisphere. Medial and lateral sagittal sections (cfr Fig. 4a for 
schematic presentation) of the contralateral hemisphere at different 
times p.i. are presented (II, IV), demonstrating spreading of Tau-
pathology to distant brain regions along neuronal connections (scale 
bar overviews—2000 µm, ×4—1000 µm). III Biochemical analysis 
of spreading of Tau-pathology to ipsilateral frontal cortex. West-
ern blotting of total homogenate (frontal cortex) revealed a charac-
teristic mobility shift (AT8 antibody) and sarkosyl insoluble Tau in 
frontal cortex extracts following Tau seeding in EC while absent in 
non-seeded Tau mice (AD-2 antibody). Quantitative analysis revealed 
significant increased ratio of sarkosyl insoluble to sarkosyl soluble 
Tau in frontal cortex following Tau-seeding in EC (n = 3 per condi-
tion; mean ± SEM are presented; *p < 0.05)
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dye [44, 55]. Spontaneous calcium oscillations were rather 
limited in primary wild-type neurons, while amplitudes 
increased in TauP301S expressing primary neurons, and 
were significantly more pronounced and well-synchro-
nized in Tau-seeded TauP301S expressing neurons [control 
(5.50 ± 0.67); Tau-neurons (10.49 ± 0.39); Tau-seeded 
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Tau-neurons (17.89 ± 0.78)] (Fig. 1b). Addition of picro-
toxin (PTX)—a non-competitive GABAAR-antagonist—
known to induce seizures similar as PTZ—in wild-type 
neurons, increased robustly the amplitude of the oscilla-
tions [no PTX (5.50 ± 0.67), with PTX (64.59 ± 3.24)], 
increased the number of synchronously oscillating neu-
rons and induced regularly shaped responses (character-
ized by a steep rise and slower decay), as reported previ-
ously [44] (Fig. 1b). Of note, similar but less pronounced 
changes as PTX application are observed when comparing 
Tau-seeded with non-seeded Tau-expressing and wild-type 
neurons in unstimulated conditions. This suggests that Tau-
seed induced Tau-aggregation acts similar as a GABAAR-
antagonist, resulting in impaired GABA-ergic transmission. 
We further identified PTX-induced calcium oscillations 
as excitatory AMPA- and NMDA-dependent oscillations 
as they were completely blocked following application of 
CNQX and D-APV (Fig. S2b), as shown previously [44]. 
Intriguingly, amplitudes of PTX-induced calcium oscilla-
tions were significantly lower in Tau-seeded Tau-express-
ing neurons (45.53 ± 2.18) compared to non-seeded 
Tau-expressing (54.51 ± 3.25) or to wild-type neurons 
(64.59 ± 3.24), indicating that also excitatory transmis-
sion was impaired following Tau-seeding (Fig. 1b). Impor-
tantly, Tau-seeding in WT—non-transgenic—neurons 
did not induce Tau-aggregation as analyzed by AT8 stain-
ing, and did not affect spontaneous nor PTX-induced cal-
cium oscillations (Fig. S2a, b). Taken together, analysis of 
spontaneous and PTX-induced neuronal network activity, 
demonstrated significantly different responses in control, 
Tau-expressing and Tau-seeded Tau-expressing neurons, 
suggesting impaired GABA-ergic and excitatory synaptic 
transmission following Tau-seeding. Hence, Tau-seeding 
affects neuronal and neuronal network function. It must be 
noted that only 5–10 % of Tau-seeded neurons displayed 
strong somatic AT8 staining. Thus, either a few neurons can 
have a robust impact on neuronal network activity, or alter-
natively and most parsimoniously, other pathological forms 
of Tau contribute to impaired neuronal network function.
Synthetic Tau seed induced Tau‑aggregation impaired 
basal synaptic transmission and synaptic plasticity 
in organotypic hippocampal slices
We next extended our assay ex vivo, in organotypic hip-
pocampal cultures derived from 6 days old Tau P301S 
transgenic pups [64, 73]. Consecutive addition of Tau-
seeds at DIV3 and DIV6 induced robust Tau-aggregation 
in hippocampal CA1 neurons 10 days after the first seed-
ing, demonstrated by AT8 staining in hippocampal slices 
while absent in non-seeded hippocampal Tau slices or in 
seeded and non-seeded hippocampal slices derived from 
non-transgenic mice (Fig. 2a). Basal synaptic excitability 
as well as synaptic plasticity were measured in hippocam-
pal CA1 region following stimulation of Schaffer collater-
als. This revealed impaired population spikes, after 10 days 
of seed induced Tau aggregation in Tau hippocampal slices. 
No significant changes in basal synaptic excitability were 
detected in wild-type hippocampal slices 10 days after Tau-
seeding, nor in Tau-expressing hippocampal slices at 2 or 
4 days after seeding (Fig. 2b). This indicates that sufficient 
induction of Tau-aggregation is required to induce synaptic 
dysfunction. Furthermore, long-term potentiation of popu-
lation spikes amplitude induced by tetanic stimulation of 
Schaffer collaterals revealed impaired synaptic plasticity 
in Tau-seeded compared to non-seeded Tau hippocampal 
slices (Fig. 2b). Our data indicate significantly impaired 
synaptic plasticity and basal synaptic function by Tau-seed 
induced Tau-aggregation.
Tau aggregation following seeding with synthetic 
pre‑aggregated Tau spreads to synaptically 
and functionally connected brain regions in TauP301S 
transgenic mice
To extend our assay in vivo, Tau-seeds were injected in 
frontal cortex and hippocampus of TauP301S mice and 
analyzed for Tau-aggregation in vivo. TauP301S transgenic 
mice develop Tau hyperphosphorylation, robust Tau-pathol-
ogy, astro- and microgliosis, hippocampal atrophy, subtle 
defects in synaptic plasticity and motoric deficits, followed 
by the development of a progressive neurodegenerative 
phenotype characterized by initial clasping, hindlimb paral-
ysis, development of hunchback, followed by premature 
death [73]. In the colony bred in our lab, this phenotype 
Fig. 4  Seeding and spreading of Tau-aggregation according to con-
nectivity rather than proximity and along disease relevant patterns. 
Seeding and spreading of Tau-pathology following injection of 
Tau-PFFs in entorhinal cortex (b), in substantia nigra (c) or in fron-
tal cortex and hippocampus (d), injection sites and sections used for 
analysis are schematically presented in a (modified after Allen Mouse 
Brain Atlas, website: http://mouse.brain-map.org/). Distinct pat-
terns of Tau-pathology are observed. b Six months post-injection in 
entorhinal cortex; AT8 staining is detected in entorhinal cortex (EC), 
hippocampal Cornu Ammonis (CA1), subiculum (Sub), amygdala 
(AA), thalamus (Thal) and frontal cortex (FrCx) (right panel). An 
overview of AT8 staining of a section closely to the medial longitu-
dinal fissure and a more lateral section are presented (left panel). c 
Six months post-seeding in substantia nigra; AT8 staining is detected 
in substantia nigra (SN), striatum (STR), thalamus (Thal), brain stem 
(BS) and motor cortex (Cx). AT8 stained neurons were also detected 
with AT100 antibody. d Six months post-injection in frontal cortex 
and hippocampus, Tau-pathology was observed at the contralateral 
hemisphere in cortical (Cx) and hippocampal (HC; CA1) regions, but 
less pronounced (marked as contra; lower row). e AT8 stainings used 
throughout this analysis matched with Gallyas silver and ThioS stain-
ings, as demonstrated in different brain regions (Cx; CA1; CA3, Sub; 
EC; AA) (scale bar overviews—2000 µm, ×4—1000 µm, ×10—
400 µm, ×20—200 µm)
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starts at around 10–11 months [35, 63]. Hence, TauP301S 
mice were used for the Tau-seeding assay at the age of 
3 months and analyzed 6 months post-injection—or ear-
lier—before robust Tau-pathology or phenotypic changes 
were detected in non-seeded TauP301S mice. After a sin-
gle injection of Tau-seeds in frontal cortex and hippocam-
pus, robust Tau-pathology was demonstrated while practi-
cally absent in control injected, non-seeded TauP301S mice 
(Fig. 3aI). Biochemical analysis demonstrated the presence 
of sarkosyl insoluble Tau-aggregates following Tau-seeding 
(Fig. 3aII). Pathological Tau-alterations—including the 
characteristic 68 kDa Tau—were revealed by immunoblot-
ting of sarkosyl insoluble and soluble fractions with anti-
total Tau (HT7) antibody, anti-Tau P-S202/T205 (AT8) 
antibody, anti-Tau P-T181 (AT270) antibody and anti-Tau 
P-T212/TS214 (AT100) antibody (not shown) and by the 
characteristic mobility shift between sarkosyl soluble and 
sarkosyl insoluble Tau (Fig. 3aII). The presence of fully 
mature NFTs, containing fibrillary Tau, was further con-
firmed by Gallyas silver and ThioS staining (Fig. 3aI).
To mimic the spreading pattern of Tau-pathology as 
observed in AD, we injected Tau-seeds in entorhinal cortex 
(EC) (Figs. 3b, 4b). Tau pathology was initially restricted 
to EC at 1.5 months post-injection, while gradually extend-
ing to functionally connected brain regions over time 
(Fig. 3bI). From 3.5 months post-injection onwards Tau 
pathology had spread to hippocampus, amygdala and corti-
cal regions remote from the injection site (Fig. 3bI). NFTs 
were detected in EC, subiculum, hippocampal formation, 
amygdala, thalamus and frontal cortex (Fig. 3bI). Further-
more, Tau aggregation was also progressively induced in 
the contralateral hemisphere (Fig. 3bII, IV). Biochemical 
analysis of Tau-pathology confirmed the presence of aggre-
gated Tau remote from the injection site, following dissec-
tion of ipsilateral frontal cortex of TauP301S mice 6 months 
post-injection in EC (Fig. 3bIII). This was also reflected in 
the characteristic shift in mobility in SDS PAGE of Tau in 
total brain extracts and increased ratio of sarkosyl insolu-
ble to sarkosyl soluble Tau, with a pronounced presence 
of the 68 kDa band in the sarkosyl insoluble Tau fraction 
compared to non-injected mice. Noteworthy, injection of 
Tau-seeds in EC of non-transgenic mice did not induce 
Tau-pathology, detectable by AT8 staining analyzed 3.5 and 
12 months post-injection (Fig. S4).
We next initiated Tau-pathology in basal ganglia, a brain 
region involved in different functions including motor 
control, as reflected in its dysfunction in Parkinson’s dis-
ease and Parkinsonism. From 3.5 months onwards and at 
6 months post-injection of Tau-seeds in basal ganglia (in 
substantia nigra) Tau aggregation was detected in striatum, 
thalamus, brain stem and cortical regions including the 
motor cortex (Fig. 4c). To assess patterns of spreading of 
Tau-pathology semi-quantitatively we generated averaged 
heat maps of AT8-stained Tau-pathology in different mice, 
6 months post-injection (n ≥ 3 for each condition) (Fig. 5). 
Our standardized AT8 staining protocol to stain forms of 
Tau, correlating strongly with Gallyas silver and ThioS 
staining (Fig. 4e) in brains was used [63]. The respective 
heat maps demonstrated that the spreading pattern of Tau-
pathology at 6 months post-injection is dependent on the 
site of initiation and occurs along functionally connected 
brain circuits. However, it must be considered that some 
regions with a more scattered induction of Tau pathology 
including striatum and thalamus may be underrepresented 
in the heat maps. This is due to technical issues, because 
scattered NFTs are more easily leveled out compared to 
densely packed neuronal layers in the averaging process 
(Fig. 5).
Taken together, our results indicate that depending on 
the initial site of injection of Tau-seeds, i.e. cortical/hip-
pocampal, basal ganglia or entorhinal cortex (Fig. 4a–d), 
different spreading patterns of Tau-pathology to func-
tionally—and often symptomatically—connected brain 
regions was observed (Fig. 5). Spreading of Tau-pathology 
occurred by connectivity rather than proximity, raising the 
question and allowing us to analyze whether neuronal net-
work function is affected by this process.
Tau‑pathology induced by Tau‑seeding impairs synaptic 
function in hippocampal CA1 region and cognition 
in TauP301S mice
Disease-specific patterns of glucose metabolism are gen-
erally considered to reflect neuronal dysfunction and have 
been demonstrated to correlate with high NFT load in dif-
ferent Tauopathies. To analyze the functional repercussions 
of spreading of Tau-aggregation through neuronal networks 
dependent on the site of initiation, we used in first instance 
FDG-PET. Mice injected with Tau-seeds and control mice 
were subjected to small-animal FDG-PET at 6 months 
post-injection. However, no significant differences were 
detected between Tau-seeded and non-seeded mice, despite 
the presence of robust Tau-pathology (Fig. 6a). This lack 
of changes should be ascribed to a lack of neurodegenera-
tive processes induced by Tau-seeded Tau-aggregation, to 
the fact that neuronal dysfunction precedes significant 
changes in FDG-PET, or to the fact that changes in FDG-
PET measured glucose metabolism were too small to detect 
with the current technique. Although, this technique was 
used successfully to reveal differences in glucose metabo-
lism following contextual fear conditioning in rodents, and 
in different AD models [43, 46]. To gain further insight, 
we analyzed synaptic and cognitive function following 
Tau-seed induced Tau-aggregation. We assessed whether 
induction of Tau-aggregation through functional connec-
tions by Tau-seeding in EC, affected synaptic function in 
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Fig. 5  Averaged heat maps for semi-quantitative analysis of spread-
ing of Tau-pathology according to connectivity rather than proxim-
ity and along disease relevant patterns. Heat maps representing color 
scored averaged images of AT8 staining were generated for different 
injection paradigms. Heat maps of Tau mice, of Tau mice injected 
with vehicle, Tau mice injected with Tau-seeds in frontal cortex and 
hippocampus (FrCx/HC), Tau mice injected with Tau-seeds in sub-
stantia nigra (SN) and Tau mice injected with Tau-seeds in entorhi-
nal cortex (EC), generated using Image J are presented. For Tau 
mice injected in EC, 2 different sagittal sections are presented situ-
ated closely to the medial longitudinal fissure and lateral. Schematic 
illustrations of the injection site and the section used for analysis are 
presented in the first column (modified after The GENSAT Project, 
website: http://www.gensat.org). Arrows indicate the injection site. 
Representative AT8 stainings (middle column) used for semi-quanti-
tative analysis are presented for each condition, 6 months post-injec-
tion of Tau-seeds (scale bar 2000 µm). This reveals distinct patterns 
of Tau-pathology, encompassing brain regions with densely packed 
Tau-pathology, brain regions with scarcer Tau-pathology and unaf-
fected brain regions. Heat maps were generated for semi-quantitative 
analysis of Tau-pathology (right column) by averaging AT8 stainings 
of multiple mice for each injection paradigm using Image J (n ≥ 3 for 
each condition). This demonstrates distinct patterns depending on the 
injection site, along functionally connected brain regions
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hippocampal neurons of CA1 following stimulation of the 
Schaffer collaterals 6 months post-seeding. Analysis of syn-
aptic plasticity demonstrated a defect in LTP following Tau-
aggregation in hippocampal CA1 neurons after induction 
of Tau-seeding in EC, while basal synaptic transmission 
was not affected in hippocampal CA1 neurons (Fig. 6b). 
Synaptic fatigue and paired pulse ratio—generally consid-
ered parameters of presynaptic function—were not affected 
by Tau-seeding, suggesting a postsynaptic rather than pre-
synaptic deficit (Fig. S3). In line with this, immunohisto-
logical staining with the presynaptic marker SV2 revealed 
no alterations following Tau-seeding in entorhinal cortex 
Fig. 6  Functional repercussions of Tau seed induced Tau-aggregation 
along unique neuronal networks, analyzed at 6 months post-injec-
tion. a FDG-PET analysis: mean horizontal small-animal FDG-PET 
images of the brain showing two representative samples of Tau-
seeded and non-seeded Tau mice. Color bars indicate standardized 
uptake values for [18F]FDG. Quantitative analysis of the standard-
ized uptake value revealed no significant difference between the dif-
ferent analyzed groups [non-transgenic (WT), non-seeded Tau trans-
genic (Tau), Tau-seeded Tau transgenic mice (Tau-seeded); n = 3 per 
group]. b Tau-seeded Tau-aggregation causes synaptic and cognitive 
dysfunction. Electrophysiological analysis of Tau transgenic mice 
seeded in entorhinal cortex or non-seeded analyzed 6 months post-
injection reveals no significantly altered basic synaptic transmission 
in hippocampal CA1 region [Tau-seeded (n = 12); Tau (n = 12)]. 
Long term potentiation (LTP) induced by tetanic stimulation of 
Schaffer collaterals was significantly impaired following seeding 
in EC, 6 months post-injection [Tau-seeded (n = 5); Tau (n = 6); 
mean ± SEM are presented; p value <0.05; Student’s t test]. Cog-
nitive function measured by the object recognition task (b, lower 
panel). Tau-transgenic mice with bilateral injection of Tau-seeds dis-
played significantly impaired object recognition memory compared to 
non-seeded Tau-transgenic mice or non-transgenic WT mice, while 
Tau transgenic mice were not significantly different compared to non-
transgenic WT mice [n = 10 (control), n = 8 (non-seeded Tau trans-
genic mice), n = 8 (Tau-seeded Tau transgenic mice); mean ± SEM 
are presented; *p value <0.05; single ANOVA, post-Dunnett’s test]. 
c Motor impairment following initiation of Tau-seeding in basal gan-
glia, but not in entorhinal cortex. Representative images of clasping 
scores are presented (upper panel) from left to right: score 5 (no 
clasping); score 3 (intermediate clasping); score 1 (severe clasping). 
Clasping and inverted grid hanging was assessed for wild type mice 
(WT; n = 12), non-injected Tau mice (Tau; n = 6), Tau mice follow-
ing Tau-seeding in entorhinal cortex (EC-Tau-seeded; n = 5), and 
Tau-mice following seeding in basal ganglia (BG-Tau-seeded; n = 7) 
6 months post-seeding. Quantitative analysis revealed significantly 
increased clasping and impaired inverted grid hanging in Tau mice 
following seeding in basal ganglia, compared to Tau mice seeded in 
EC, Tau mice and non-transgenic mice (mean ± SEM are presented; 
*p value <0.05; one-way ANOVA, post-Dunnett’s test). In the graph 
in panel c, non-injected Tau-mice are presented for comparison with 
Tau-seeds injections in EC and basal ganglia. Sham injections in 
Tau mice in basal ganglia [clasping score: 3.9 ± 0.4, inverted grid 
hanging: 98.9 ± 12.7 (mean ± SEM, n = 9)] did not alter clasping 
or inverted grid hanging scores compared to non-injected Tau mice 
[clasping score: 3.8 ± 0.2, inverted grid hanging: 109.4 ± 10.0 
(mean ± SEM, n = 6)] (not presented in the graph)
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(results not shown). Long-term potentiation is generally 
believed to present a cellular model of learning and mem-
ory formation, and is induced during learning in CA1 [71]. 
Therefore, we assessed hippocampus-dependent cognitive 
function following Tau-seed induced Tau-aggregation. We 
first measured cognitive function after unilateral injection 
of Tau-seeds in Tau-transgenic mice, revealing no signifi-
cant changes between unilateral Tau-seeded mice and non-
seeded mice (results not shown). We next assessed cogni-
tive function, 6 months following bilateral injections. This 
revealed a significant deficit in object recognition memory 
1 h post-training in Tau-seeded mice compared to non-
seeded mice (Fig. 6b). Our data thereby demonstrate that 
Tau-seeded Tau-aggregation is associated with impaired 
cognition in Tau-transgenic mice.
Spreading of Tau aggregation along neuronal circuitries 
and impairment of associated behavioral outcomes is 
determined by the site of initial seeding in TauP301S 
mice
We next analyzed whether the site of initiation of Tau-
aggregation determines the specific behavioral outcomes. 
We measured motoric performance 6 months after ini-
tiation of Tau pathology in basal ganglia and EC, respec-
tively. Quantitative scoring of hindlimb clasping revealed 
significantly increased clasping following initiation of 
Tau-pathology in basal ganglia, compared to initiation of 
Tau-pathology in EC, which did not induce significant 
clasping (Fig. 6c). Furthermore, we measured inverted 
grid hanging performance, to assess motor coordination 
and grip strength. Performance in inverted grid hanging 
was severely impaired 6 months post-initiation of Tau-
aggregation by Tau-seeding in basal ganglia, while not sig-
nificantly affected 6 months post-seeding in EC (Fig. 6c). 
Intracerebral injections of buffer only in basal ganglia did 
not induce Tau-aggregation and did not affect clasping or 
inverted grid hanging (Fig. 6c). Taken together, our data 
indicate that prion-like seeding of Tau-aggregation along 
synaptic connections affects selective functional brain cir-
cuitries, thereby determining the behavioral dysfunction 
depending on the site of initiation of Tau-pathology.
“Early” pathological forms of Tau rather than fully 
mature NFTs as causal culprits for neuronal 
dysfunction
To gain insight in potential forms of Tau responsible for 
the neuronal network dysfunction observed in our models, 
we performed biochemical and immunological analyses. 
We first assessed the induction of pathological Tau-forms 
in brains in vivo following Tau-seeding. Immunohisto-
logical analysis demonstrated the presence of misfolded 
Tau (MC1) and Tau hyperphosphorylated at pathologi-
cal epitopes S202/T205 (AT8) and T212/S214 (AT100) 
(Fig. 7a). The presence of fully mature NFTs was further 
confirmed by Gallyas silver staining and ThioS staining 
(Figs. 3aI, 4e). Finally, electron microscopy (EM) analy-
sis confirmed the clear presence of Tau fibrils and aggre-
gated Tau (Fig. S5). Dot blot analysis with T22 antibody 
[40], demonstrated accumulation of Tau-oligomers in 
total homogenates following Tau-seeding (Fig. 7b). Tau-
multimers were further analyzed in total homogenates 
in non-denaturing and non-reducing conditions in native 
PAGE. Larger Tau-aggregates, i.e. granular Tau (~40 Tau-
molecules, 2.4 MDa) and fibrillary Tau, cannot enter the 
gel under these conditions. AT8 positive Tau-multimers 
were increased in brains following Tau-seeding (Fig. S6). 
To gain more insight in early pathological forms of Tau, 
we performed a more detailed immunohistological analy-
sis using AT8 staining. This demonstrated the presence of 
clearcut NFTs, which we previously demonstrated to cor-
relate with Silver staining and ThioS staining in brains, 
but using more sensitive settings also different forms of 
AT8-stained Tau were revealed. More particularly, neurons 
with different stages of Tau-pathology ranging from early 
to fully mature NFTs were observed. In addition, diffuse 
and punctate staining patterns were observed in broader 
regions than regions displaying mature NFTs (Fig. 7c). 
This diffuse and punctate staining was markedly induced 
by Tau-seeding (Fig. S7) and observed in cell bodies but 
also very prominently in neuritic extensions of neurons. 
Taken together, Tau-seeding propagated diverse pathologi-
cal Tau forms ranging from clearcut mature NFTs (somatic 
fibrillar Tau-aggregates) to “early” pathological forms of 
Tau, encompassing more diffuse and punctate AT8, as well 
as hyperphosphorylated, misfolded (MC1) and oligomeric 
Tau forms (stained with T22 or AT8).
We next analyzed the presence of these different forms 
of Tau following Tau-seed induced Tau-aggregation in 
primary neurons (PNC) and organotypic cultures (OC) 
(Fig. 7). Tau-seeding induced more robust and more abun-
dant AT8 staining in organotypic hippocampal slices than in 
primary neurons, due to higher concentrations of Tau-seeds 
and topical application of the seeds on the slice. In primary 
neurons Tau-seed induced Tau-aggregation was less robust 
than previously published [27] since lower concentrations 
of Tau-seeds were used. Immunological analysis revealed 
the presence of pathological forms of Tau reflected by 
AT8, AT100 and MC1 positive signals in both models, OC 
and PNC (Fig. 7a). EM analysis revealed the presence of 
Tau fibrils in OC following Tau seeding, albeit less abun-
dant than in brains (Fig. S5). Fibrils were not detected by 
EM analysis in primary neurons, paralleled by the lack of 
ThioS staining in PNC (results not shown). This indicates 
that fully mature Tau-fibrils were absent or present in very 
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low quantities below detection limit of the assay (EM and 
ThioS) in PNC. Oligomeric Tau forms were increased 
in primary neurons and organotypic cultures as demon-
strated by dot blotting with the Tau oligomer-specific T22 
antibody (Fig. 7b). In both models, Tau-seeding increased 
AT8-positive Tau-multimers detected in Native PAGE (Fig. 
S6). To further analyze early pathological forms of Tau 
in PNC, we performed a more sensitive AT8 staining, by 
omitting the stringent extraction of soluble forms of Tau, 
thereby staining both aggregated and soluble forms of AT8-
stained Tau. This revealed marked Tau-seed induced diffuse 
and punctate AT8-staining, in addition to the somatic Tau-
aggregation as previously detected (Fig. 7c). As indicated 
above, strong somatic NFT-like Tau-staining of aggregated 
Tau was only observed in 5–10 % of the neurons in PNC. 
In contrast, the punctate and more diffuse staining pattern 
was robustly observed throughout the culture (Fig. 7c), and 
was markedly induced by Tau-seeding in Tau-expressing 
neurons and absent in wild-type neurons (Fig. S7). This 
punctate and diffuse staining pattern was also observed in 
neurons not yet displaying strong NFT-like somatic AT8 
signal, hence representing an early form of pathologi-
cal AT8 positive Tau. In view of the detection of somatic 
aggregated Tau in only very limited number of neurons, 
and the inability to detect fibrillar Tau in primary neurons 
following Tau-seeding using EM and ThioS, the combined 
data point to early pathological forms of Tau, encompass-
ing non-NFT AT8-positive Tau and oligomeric Tau, rather 
than fully mature fibrillary NFTs, as culprit for Tau-seed 
induced neuronal dysfunction in PNC. The clearcut pres-
ence of these early pathological Tau-forms in brains and 
organotypic hippocampal slices following Tau-seeding, 
further supports their potential role in neuronal dysfunction 
in all models. Taken together, our data suggest that early 
pathological forms, encompassing diffuse and punctate 
AT8 stained Tau, hyperphosphorylated, misfolded (MC1) 
and oligomeric Tau forms (stained with T22 or AT8), rather 
than fully mature NFT, correlate with the neuronal dys-
function induced by Tau-seeded Tau-misfolding.
Discussion
Accumulating evidence has demonstrated that Tau displays 
prion-like properties and that prion-like spreading of Tau-
pathology occurs through connectivity rather than prox-
imity [1]. This process has been proposed to underlie the 
stereotyped progression along unique brain circuitries of 
Tau-pathology and symptoms in Tauopathies [22, 28, 50, 
53, 58, 74]. In this work, we demonstrated—for the first 
time—that templated Tau-misfolding induced by Tau-seeds 
through functionally connected neuro-anatomical path-
ways, impairs neuronal network function and associated 
behavioral outcomes, dependent on the initial site of seed-
ing. More precisely, we demonstrated that small amounts 
of pre-aggregated synthetic Tau fragments, focally injected, 
without changing expression-level of Tau but only inducing 
Tau-misfolding, are sufficient to propagate Tau aggrega-
tion and impair neuronal network function and behavioral 
outcomes 6 months post-injection, dependent on the initial 
site of injection. These findings emphasize the potential rel-
evance of this intensively studied process in the stereotypic 
progression of symptoms in Tauopathies. We have further 
extended our analysis to highlight early pathological forms 
of Tau, rather than fully mature fibrillar NFTs as causal cul-
prits for the neuronal network dysfunction.
We demonstrated that templated Tau-misfolding by 
Tau-seeds affected neuronal network activity in primary 
neuronal cultures. Primary cortical neurons display syn-
chronized calcium oscillations in culture, which were pre-
viously shown to be modulated by PTX, a GABAA recep-
tor antagonist [44]. Exposure of cortical neurons to PTX 
renders calcium transients to exhibit increased amplitude, 
more regular frequency and higher synchronicity [44]. A 
refractory period has previously been identified which may 
play a role in increased synchronization. Our data indi-
cate a significant dysregulation of spontaneous and PTX-
induced calcium oscillations, indicating that Tau-seeded 
Tau-misfolding affects neuronal network activity. Our 
findings suggest that Tau-seeding impairs GABA-ergic 
synaptic transmission, based on the similarity of the effect 
of PTX and Tau-seeds on spontaneous oscillations. As we 
Fig. 7  Different pathological forms of Tau are generated by Tau-seed 
induced Tau-aggregation. a Immunostaining of pathological forms of 
Tau reveals the presence of hyperphosphorylated Tau forms phospho-
rylated at Ser202/Thr205 (AT8) and T212/S214 (AT100), as well as 
misfolded Tau (MC1) antibody in all models, i.e. HEK293, brains, 
organotypic cultures and primary neurons, following Tau-seeding 
(scale bar ×20—200 µm, ×40—100 µm). b Tau-seeding increased 
Tau-oligomer concentrations assessed by dot blotting analysis with 
the Tau-oligomer specific T22 antibody on total homogenates. Quan-
titative analysis demonstrated accumulation of oligomeric Tau forms 
following Tau-seeding in brains [(n = 4; n = 4), (non-seeded; Tau-
seeded)], organotypic cultures (OC) (n = 5; n = 5) and primary neu-
rons (PNC) (n = 6; n = 5) (mean ± SEM are presented; *p value 
<0.05). Dilution curves of samples of the different models are pre-
sented. c Immunohisto/cytological analysis with AT8 reveals differ-
ent forms of AT8 stained Tau. In addition to mature and immature 
NFTs, diffuse and punctated staining are prominently observed by 
AT8-staining in organotypic hippocampal cultures and brains follow-
ing Tau-seeding (left panels provide an overview picture and details 
of different types of AT8 staining observed in Tau-seeded OC and 
brains). In PNC, AT8 staining following standard fixation in 4 % 
PAF, demonstrates strong diffuse and punctated AT8 staining present 
throughout the culture dish in PNC, and robustly induced following 
Tau-seeding in TauP301S expressing PNC. Lower panels show AT8 
staining (standard fixation) in non-seeded primary neurons derived 
from TauP301S mice (Tau) or non-transgenic mice (WT) (scale bar 
×20–200 µm, ×40–100 µm)
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further demonstrated that PTX elicited calcium transients 
are NMDA- and AMPA-dependent as shown previously 
[44], their reduced amplitudes in Tau-seeded neuronal cul-
tures indicate impaired glutamatergic, NMDA- and AMPA-
dependent signaling. We further extended our analysis in 
models with conserved network architecture, i.e. to organo-
typic hippocampal slices [21]. In organotypic cultures, 
we demonstrated impaired population spike amplitude 
measured in hippocampal CA1 region following stimula-
tion of Schaffer collaterals. This basal synaptic transmis-
sion is predominantly generated by excitatory glutamater-
gic (NMDA/AMPA-mediated) neurotransmission, further 
corroborating data obtained in primary neuronal cultures. 
Furthermore, measurement of LTP revealed that synap-
tic plasticity is impaired in organotypic slices by Tau-seed 
induced Tau misfolding. Notably, NMDA- and AMPA-
receptor functions are critically involved in hippocampal 
LTP in CA1. Our data were further corroborated in vivo. 
Electrophysiological analysis in acute hippocampal slices 
revealed that LTP was affected 6 months post-induction of 
Tau-pathology by Tau-seeding in vivo, although basic syn-
aptic transmission was not. The latter may be explained by 
the fact that effects of Tau-aggregation can be more easily 
compensated in vivo than in vitro, or that the aggregation 
process occurred more rapidly in vitro, or that organotypic 
cultures are more sensitive than the intact hippocampus in 
vivo. It must be noted that electrophysiological analysis in 
acute hippocampal slices was performed in hippocampal 
CA1 region, while initial Tau-seeding was performed in 
entorhinal cortex, indicating that neuronal function remote 
from the initial seeding site was affected. We further dem-
onstrated conserved presynaptic parameters including 
paired pulse ratio, synaptic fatigue and SV2 staining, point-
ing towards a postsynaptic mechanism. Together with the 
results obtained in primary neurons, indicating impaired 
NMDA/AMPA-dependent neuronal network function 
following Tau-seeding, our data are in line with a role of 
pathological Tau forms in postsynaptic dysfunction, includ-
ing NMDA/AMPA dysfunction as previously shown [8, 
60, 70]. We further assessed behavioral effects, and dem-
onstrated that cognition, measured in an object recognition 
task was impaired in bilaterally injected mice, 6 months 
post-injection. Together our data indicate that Tau-seed 
induced misfolding of Tau, leading to Tau-aggregation 
through connectivity, affects neuronal function, neuronal 
network activity and behavioral outcome, and hence could 
contribute to progression of the symptoms in Tauopathies.
Prion like induction of Tau-pathology—a process which 
raised considerable scientific interest—has been elegantly 
demonstrated and analyzed in exquisite detail for different 
aspects [1, 12–14, 19, 20, 22, 26, 28, 32, 35, 37, 40, 53, 72]. 
The functional repercussions of this process remained how-
ever, to be analyzed. This question is important to evaluate 
its relevance in the pathogenetic process of Tauopathies. In 
AD, Tau-pathology is known to progress according to ste-
reotypical and predictable patterns reflected in its incorpo-
ration in criteria for the neuropathological diagnosis of AD 
[6, 34]. The first neurons to be affected are in entorhinal 
cortex (EC) (stage I), the neurons that give rise to the per-
forant pathway, the major projection connecting cerebral 
cortex with the hippocampus [23, 33]. Next NFTs spread 
to the CA1 region of the hippocampus and accumulate in 
limbic structures such as the subiculum (stage II–III) and 
the amygdala, thalamus, and claustrum (stage IV). Finally, 
NFTs spread to isocortical areas (stage V–VI). Symp-
toms in AD are strongly correlated with this characteristic 
appearance of NFTs. In this work, we mimic spreading of 
Tau-pathology following seeding in entorhinal cortex of 
TauP301S mice, similar as observed in AD. Tau pathology 
starts first in the entorhinal cortex, subsequently in CA1, 
the subiculum and CA3-4 and later in the DG, and finally in 
neocortical areas (stages V and IV), according to the Braak 
and Braak stages. Noteworthy, minor discrepancy between 
spreading of Tau-pathology in AD [EC, subsequently CA1/
subiculum/CA3-4 and later dentate gyrus (DG)] and func-
tional connectivity (EC, subsequently DG/CA3-4 and then 
CA1/subiculum) may be ascribed to additional factors 
determining selective vulnerability or protection in these 
regions, which appear to be recapitulated in our model, as 
the AD pattern was mimicked following seeding in EC. It 
must be noted however that in contrast to AD and sporadic 
Tauopathies, characterized by aggregation of wild type Tau, 
we used in the current work recipient Tau and inducer Tau-
seeds mutated at Proline 301, as this combination results in 
the highest Tau-aggregation efficiency. Previous work also 
indicated that mutation of Proline 301, rather than its sub-
stitution by Serine or Leucine, is determining aggregation 
efficiency [27]. However, wild type Tau acting as recipient, 
in combination with either wild-type or mutant Tau seeds 
as inducer has been demonstrated to be capable of prion-
like Tau seeding, albeit much less efficient. The potential 
of wild type Tau to undergo prion-like Tau seeding allows a 
(cautious) extrapolation of our data in the context of AD or 
sporadic Tauopathies, characterized by aggregation of wild 
type Tau. Hence, neuronal network dysfunction and associ-
ated behavioral dysfunctions induced by prion-like seeding 
and spreading of Tau-pathology along functionally con-
nected circuitries could relate to symptomatic progression 
in AD and related Tauopathies.
Besides in AD patients, spreading of Tau-aggregation 
according to a characteristic pattern along functionally 
connected brain circuitries is also observed in argyroph-
ilic grain disease, a different Tauopathy. Other Tauopathies 
are very heterogeneous between individuals with identi-
cal mutations, including for patients with Tau mutated 
at Proline 301 (P301L) [4]. This heterogeneity hampers 
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the delineation of a specific progression pattern. How-
ever, symptoms progressively affect certain behaviors 
driven by a particular brain circuitry. We here demon-
strate for the first time that the initial site of Tau-seeding 
determines the behavioral outcomes, resulting in different 
behavioral outcomes depending on the initiation site. Ini-
tiation of prion-like seeding in transgenic mice express-
ing mutant TauP301S, in entorhinal cortex resulted in 
spreading of Tau-pathology along functionally connected 
circuits, resulting in impaired LTP in hippocampal CA1 
neurons. Cognition measured in an object recognition task 
was demonstrated to be impaired following Tau-seeded 
Tau-aggregation. In contrast, prion-like seeding in basal 
ganglia resulted in spreading to brain regions involved in 
motor control, thereby resulting in motor impairments, 
6 months after Tau-seeding. Motoric impairments were not 
observed following injection of Tau-seeds in EC. These 
findings are reminiscent of the heterogeneity of symptoms 
in TauP301 patients, where the initial site of Tau seeding 
by environmental, genetic or accidental factors, may deter-
mine the symptomatic outcome (cognitive symptoms or 
Parkinsonism).
The clearcut demonstration of impaired neuronal net-
work function and behavior by prion-like seeding raises 
questions about the causal culprit, in terms of pathological 
forms of Tau. The combination of our functional analysis 
with biochemical and immunological analysis points to 
early pathological forms of Tau, including pathological 
hyperphosphorylated and misfolded Tau and Tau oligom-
ers rather than fully mature NFTs as potential pathologi-
cal culprits. Notably, strong somatic AT8 aggregation was 
only observed in 5–10 % of neurons following Tau-seed-
ing in primary neurons. Furthermore, the presence of fully 
mature fibrils was below detection limit using electron 
microscopy and ThioS staining was not observed in PNC. 
It must be noted that Tau-seeding in primary neurons in 
this work was less robust than previously published [27], 
probably due to lower concentration of Tau-seeds used. 
We have however, demonstrated the abundant presence 
of “early” AT8-positive forms of Tau detected as diffuse 
staining and punctated synaptic staining in the current 
model. This staining was present throughout the primary 
neuronal culture and robustly induced following Tau-seed-
ing. Furthermore, oligomeric forms of Tau stained with 
T22 or with AT8 were increased following Tau-seeding in 
all models. Although an approximately, twofold increase 
may seem rather low, the spatio-temporal characteristics 
(e.g. at the synapse) of this increase may underlay its pro-
nounced effect on neuronal function. Taken together our 
data indicate that either a few neurons displaying strong 
somatic AT8 staining are responsible for impaired neu-
ronal network activity, or most parsimoniously, that early 
forms of aggregated Tau or “pre-tangle stage” pathological 
forms of Tau, are responsible for neuronal network dys-
function. This is further supported by their abundant 
induction in brains and in organotypic cultures following 
Tau-seeding. Taken together our data suggest that early 
pathological forms of Tau rather than fully mature NFTs 
may represent the causal culprits. Final proof can only be 
delivered by selective elimination of different pathological 
forms of Tau and analysis of the functional repercussions. 
Our observations fit however with previous observations 
using elegant approaches to determine the repercussions of 
Tau-pathology, and more particularly of NFTs on neuronal 
function in vivo [18, 30, 38, 48, 52, 54, 61, 65, 66, 69]. 
This demonstrated either no effects of NFTs in neurons 
on calcium or Arc responses [38, 52]. Furthermore, using 
inducible expression of Tau or pro-aggregant Tau, revers-
ibility of synaptic deficits despite the continued presence 
of NFTs was demonstrated, indicating association of syn-
aptic defects with the aggregation process and early patho-
logical Tau forms, rather than with the full-blown NFTs [3, 
30, 54, 61, 65, 66, 69]. These data are in line with clear 
demonstration of detrimental effects of Tau-oligomers on 
neuronal function and behavior, as demonstrated following 
acute injection of oligomeric Tau and immunization with 
anti-Tau oligomeric antibodies [10, 11, 39, 40]. Our find-
ings are furthermore in line with previous reports demon-
strating that Tau overexpression or Tau-alterations affect 
neuronal function or function of connected neurons [29, 
31, 42, 47, 48, 56, 57, 63, 73]. It must be noted that in the 
current work, Tau-expression is not affected, but only mis-
folding of Tau is induced by templated seeding by focal 
administration of small amounts of seeds. We demonstrate 
that this templated Tau-misfolding is sufficient to propa-
gate neuronal network dysfunction and behavioral out-
comes, which correlate with the presence of early patho-
logical forms of Tau, including Tau oligomers, rather than 
with the presence of fully mature Tau fibrils.
In summary, our data indicate for the first time and une-
quivocally, using in vitro, ex vivo and in vivo approaches 
that (i) prion-like Tau-seed induced Tau-aggregation with 
NFT formation—a mechanism under intensive investiga-
tion—causes synaptic and neuronal network dysfunction, 
resulting in behavioral impairments. Our data thereby indi-
cate that prion-like spreading of Tau-pathology may con-
tribute to progression of disease symptoms in Tauopathies 
by affecting intrinsic functional critical networks. Further-
more, our data indicate unequivocally that (ii) behavioral 
outcomes following seeding in Tau P301 transgenic mice, 
are determined by the initial site of Tau seeding. Hence, 
motoric problems were demonstrated following Tau-seed-
ing in basal ganglia (substantia nigra), while absent fol-
lowing injection in entorhinal cortex, resulting in cognitive 
defects. These findings are reminiscent of the heterogeneity 
of clinical symptoms in familial cases with P301 mutations, 
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in which initial seed formation by environmental, genetic 
or accidental factors, may determine the behavioral out-
comes. Finally, (iii) our results support a role of early 
pathological forms of Tau, including oligomeric Tau rather 
than fully mature NFTs as pathogenic culprits of prion-like 
induced spreading of neuronal dysfunction. Our findings 
provide a basis to further identify the molecular mecha-
nisms involved in Tau-seed induced synaptic dysfunction 
and provide a model to develop novel therapeutic strategies 
targeting Tau-seed induced neuronal dysfunction, and to 
analyze repercussions on neuronal function induced by dif-
ferent Tau-“strains”.
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